NCT06839872 2025-06-05
BOSS
AstraZeneca
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT04660045 2022-04-05
Early Intervention With Acalabrutinib in Patients With High Risk CLL
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT04961801 2022-03-08
Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Withdrawn